Wide Ranks

EYEN

Eyenovia, Inc.

0.0929

Top Statistics
Market Cap 8 M Forward PE -0.2239 Revenue Growth 0.00 %
Current Ratio 0.46 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.13 Enterprise / Revenue 1256.65 Price To Sales Trailing12 Months 282.33
Profitability
Profit Margins 0.00 % Operating Margins -51661.19 %
Balance Sheet
Total Cash 2 M Total Cash Per Share 0.0360 Total Debt 15 M
Total Debt To Equity Current Ratio 0.46 Book Value Per Share 0.1980
All Measures
Short Ratio 245.00 % Message Board Id finmb_291491698 Shares Short Prior Month 3 M
Return On Equity -9.15 City New York Uuid 7cc11ed8-2819-3a93-861a-391a3be08bb0
Previous Close 0.1090 First Trade Date Epoch Utc 1 B Book Value 0.1980
Beta 1.75 Total Debt 15 M Volume 11 M
Price To Book 0.4692 Fifty Two Week Low 0.0790 Total Cash Per Share 0.0360
Total Revenue 31405 Shares Short Previous Month Date 1 B Target Median Price 3.50
Max Age 86400 Recommendation Mean 3.00 Sand P52 Week Change 0.3133
Operating Margins -51661.19 % Target Mean Price 3.50 Net Income To Common -37281672
Short Percent Of Float 0.0268 Implied Shares Outstanding 95 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 25 M Average Volume10days 25 M
Total Cash 2 M Next Fiscal Year End 1 B Revenue Per Share 0.0010
Held Percent Insiders 0.0999 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.1090 Target Low Price 2.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.4211 Open 0.1027
Free Cashflow -18179216 State NY Dividend Yield 0.00 %
Return On Assets -0.9294 Time Zone Short Name EST Trailing Eps -0.6900
Day Low 0.0891 Address1 295 Madison Avenue Shares Outstanding 95 M
Price Hint 4 Target High Price 5.00 Website https://www.eyenovia.com
52 Week Change -0.9345 Average Volume 4 M Forward Eps -0.5300
Recommendation Key hold Compensation As Of Epoch Date 1 B Quick Ratio 17.20 %
Is_sp_500 False Regular Market Day High 0.1033 Profit Margins 0.00 %
Fifty Two Week High 2.57 Day High 0.1033 Shares Short 2 M
Regular Market Open 0.1027 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1256.65 Revenue Growth 0.00 % Shares Percent Shares Out 0.0249
Operating Cashflow -30229292 Currency USD Time Zone Full Name America/New_York
Market Cap 8 M Is_nasdaq_100 False Zip 10017
Quote Type EQUITY Industry Biotechnology Long Name Eyenovia, Inc.
Regular Market Day Low 0.0891 Held Percent Institutions 0.1373 Current Price 0.0929
Address2 Suite 2400 Enterprise To Ebitda -1.13 Financial Currency USD
Current Ratio 0.46 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 50 M Two Hundred Day Average 0.8235
Enterprise Value 39 M Price To Sales Trailing12 Months 282.33 Forward PE -0.2239
Regular Market Volume 11 M Ebitda -34802844 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics.

It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery.

The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications.

It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co.

, Ltd.

to develop and commercialize MicroPine, MicroLine, and Mydcombi.

The company has agreement with Formosa Pharmaceuticals.

Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.

05%) for the Treatment of Acute Dry Eye Disease in the U.

S.

The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.

Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.